Published in Am J Physiol Renal Physiol on July 28, 2010
A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther (2011) 1.07
Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease. AAPS J (2012) 0.98
Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8). J Pharm Sci (2013) 0.78
Mechanistic models describing active renal reabsorption and secretion: a simulation-based study. AAPS J (2012) 0.77
MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res (2004) 168.89
SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res (2003) 52.26
Human non-synonymous SNPs: server and survey. Nucleic Acids Res (2002) 50.45
Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information. Bioinformatics (2006) 17.28
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
SNAP: predict effect of non-synonymous polymorphisms on function. Nucleic Acids Res (2007) 8.46
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet (2009) 4.97
A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J Exp Med (2003) 3.30
Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos (2007) 1.97
Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem (2000) 1.60
Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol (2007) 1.60
Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet (2005) 1.57
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics (2002) 1.57
Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J Pharmacol Sci (2004) 1.52
Functional genomics of membrane transporters in human populations. Genome Res (2005) 1.27
Proline substitutions are not easily accommodated in a membrane protein. J Mol Biol (2004) 1.27
Replication of the five novel loci for uric acid concentrations and potential mediating mechanisms. Hum Mol Genet (2009) 1.25
Characterization and identification of steroid sulfate transporters of human placenta. Am J Physiol Endocrinol Metab (2002) 1.23
Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem (1995) 1.21
The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am J Physiol Renal Physiol (2005) 1.15
Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther (2002) 1.10
Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics (2007) 1.02
Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther (2002) 0.98
Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet Genomics (2005) 0.98
Functional characterization of a human organic anion transporter hOAT4 in placental BeWo cells. Eur J Pharm Sci (2005) 0.96
Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion. Pharmacol Ther (2005) 0.96
Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol (2006) 0.95
Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]. Kidney Int (2005) 0.91
Roles of organic anion transporters in the progression of chronic renal failure. Ther Apher Dial (2007) 0.90
Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4). Br J Pharmacol (2009) 0.87
Negligible validation rate for public domain stop-codon SNPs. Hum Mutat (2003) 0.85
The role of glycine residues in the function of human organic anion transporter 4. Mol Pharmacol (2004) 0.85
Mutational analysis of histidine residues in human organic anion transporter 4 (hOAT4). Biochem J (2004) 0.85
Upregulation of rat renal cortical organic anion transporter (OAT1 and OAT3) expression in response to ischemia/reperfusion injury. Am J Nephrol (2008) 0.84
Identification and characterization of single nucleotide polymorphisms of SLC22A11 (hOAT4) in Korean women osteoporosis patients. Mol Cells (2008) 0.80
Renal organic anion transporters OAT1 and OAT3 mediate the cellular accumulation of 5-sulfooxymethylfurfural, a reactive, nephrotoxic metabolite of the Maillard product 5-hydroxymethylfurfural. Biochem Pharmacol (2009) 0.79
Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4. J Pharm Pharmacol (2006) 0.79
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
Visualizing density maps with UCSF Chimera. J Struct Biol (2006) 5.75
BayGenomics: a resource of insertional mutations in mouse embryonic stem cells. Nucleic Acids Res (2003) 4.83
MODBASE, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res (2004) 4.54
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
The International Gene Trap Consortium Website: a portal to all publicly available gene trap cell lines in mouse. Nucleic Acids Res (2006) 3.40
Designed divergent evolution of enzyme function. Nature (2006) 3.09
Using sequence similarity networks for visualization of relationships across diverse protein superfamilies. PLoS One (2009) 3.03
ModBase, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res (2010) 2.96
Leveraging enzyme structure-function relationships for functional inference and experimental design: the structure-function linkage database. Biochemistry (2006) 2.65
clusterMaker: a multi-algorithm clustering plugin for Cytoscape. BMC Bioinformatics (2011) 2.56
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52
Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J Trop Med Hyg (2006) 2.43
Tools for integrated sequence-structure analysis with UCSF Chimera. BMC Bioinformatics (2006) 2.38
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
Software extensions to UCSF chimera for interactive visualization of large molecular assemblies. Structure (2005) 2.12
UCSF Chimera, MODELLER, and IMP: an integrated modeling system. J Struct Biol (2011) 2.10
The concentrative nucleoside transporter family, SLC28. Pflugers Arch (2003) 2.06
Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A (2003) 2.03
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics (2003) 1.79
Genetic modifiers of the phenotype of mice deficient in mitochondrial superoxide dismutase. Hum Mol Genet (2006) 1.68
cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. Proc Natl Acad Sci U S A (2008) 1.62
App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J Neurosci (2003) 1.59
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics (2002) 1.57
The Structure-Function Linkage Database. Nucleic Acids Res (2013) 1.50
Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics (2010) 1.48
Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci (2006) 1.48
Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A (2008) 1.47
Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics (2009) 1.46
Craniofacial phenotypes in segmentally trisomic mouse models for Down syndrome. Am J Med Genet (2002) 1.39
Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther (2006) 1.38
Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics (2012) 1.38
Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther (2011) 1.35
Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. J Pharmacol Exp Ther (2007) 1.33
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem (2011) 1.30
Renal transporters in drug development. Annu Rev Pharmacol Toxicol (2012) 1.30
Comparison of human solute carriers. Protein Sci (2010) 1.29
Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics (2003) 1.29
Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. Proc Natl Acad Sci U S A (2011) 1.29
Functional genomics of membrane transporters in human populations. Genome Res (2005) 1.27
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res (2011) 1.26
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res (2002) 1.24
The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther (2008) 1.23
Representing structure-function relationships in mechanistically diverse enzyme superfamilies. Pac Symp Biocomput (2005) 1.19
Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J (2009) 1.18
Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci (2010) 1.17
The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am J Physiol Renal Physiol (2005) 1.15